SPDS hosts Disso India-Mumbai 2017

The convention witnessed the presence of professionals from Pharma R&D, QA, QC and academia to discuss developments related to dissolution science and its applications

The Society for Pharmaceutical Dissolution Science (SPDS) organised its 5th Annual International Convention Disso India-Mumbai 2017. The convention aimed to promote introduction of new technology, innovation in the field of dissolution testing.

Disso India-Mumbai 2017 witnessed eminent professionals from the pharmaceutical industry and was attended by professionals from R&D, QA and QC as well as the academia and had deliberations on various issues related to Dissolution Science and its applications.

This event was organised under the chairmanship of Dr K Bangarurajan, Deputy Drugs Controller, DDC (India), Central Drugs Standard Control Organization, West Zone, India and the organising secretary, Dr L Ramaswamy, MD, SOTAX India.

The scientific sessions were programmed and executed under the chairmanship of Prof Padma V Devarajan, Professor in Pharmacy, Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology and Dr Vinod P Shah, Ex US FDA, Pharmaceutical Consultant, USA.

The event had plenary lectures, panel discussions, exhibits and poster sessions. Disso India 2017 had global speakers such as Dr Roger Willam, EX-CEO USP, Ex US FDA, USA, who shared an insight on regulation science: the paradigm of dissolution. Dr Vinod P Shah, Ex. US FDA, Pharmaceutical Consultant, USA, who explained the novel science-based approach for Topical drug Classification (TCS) and covered the topic of scientific basis for topical drug classification system (TCS). Prof Dr Jennifer Dressman, Institute of Pharmaceutical Technology, Biocenter, Johann Wolfgang Goethe University, Germany spoke on Gastrointestinal I physiology and need for selective dissolution media and also presented the advantages and impact of biorelevant dissolution media.

The event had few technical sessions such as Quality by Design ( QbD) implementation in Dissolution Studies – Case studies by Vijay Kshirsagar, Director and CEO, TRAC Pharma Consulting, Mumbai, India & President -SPDS; and patentability of a product based on dissolution data and data integrity issues in dissolution based factors affecting bioavailability by Prof Dr Umesh Banakar, Professor and President, Banakar Consulting Services, USA; quality metrics for better compliance by Prof Dr Raghunandan HV, Deputy Director- Academics, JSS University, Mysore; automation in dissolution testing by Michel Magnier, Product Manager and Application specialist, SOTAX, Switzerland; Complexity of invitro drug release measurements for ophthalmic drug products by Dr Chetan Pujara, Vice President, Small Molecule Product Development, Allergan, USA; drug dissolution: excipient vs excipient by Dr Abhijit V Gothoskar, Technical Advisor, Anshul Life Sciences, India; risk assessment of analytical methods w.r.t dissolution testing by Manu Grover, Waters India; incorporating physiologically based pharmacokinetic (PBPK) modelling to assist with dissolution method development, IVIVC and successful biowaivers by Dr Parizad A Elchidana, GMP Scientific and In vitro dissolution testing for nano formulations by Prof Dr Padma V Devarajan, Institute of Chemical technology, (ICT), Mumbai.